<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="629">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05152966</url>
  </required_header>
  <id_info>
    <org_study_id>CS1335</org_study_id>
    <nct_id>NCT05152966</nct_id>
  </id_info>
  <brief_title>Feasibility Study of the FARAPULSE™ Cardiac Ablation System Plus in the Treatment of Persistent Atrial Fibrillation(PersAFOne II)</brief_title>
  <acronym>PersAFOne II</acronym>
  <official_title>PersAFOne II(Pronounced Per-'Se-fa-nē 2); Feasibility Study of the FARAPULSE™ Cardiac Ablation System Plus in the Treatment of Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Farapulse, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Farapulse, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this safety and feasibility study is to assess whether the endocardial&#xD;
      creation of electrically nonconductive lesions via PEF catheter ablation applied using the&#xD;
      FARAPULSE Cardiac Ablation System Plus is a feasible and safe treatment for PersAF and&#xD;
      associated AFL&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center safety and feasibility study in subjects with persistent&#xD;
      AF. Subjects will undergo percutaneous PEF ablation for pulmonary vein isolation as well as&#xD;
      cavotricuspid isthmus interruption and other left atrial ablations at the investigator's&#xD;
      discretion. Subjects will then be followed at 30 days, 60 ± 15 days, 6 months and 12 months&#xD;
      for adverse events, recurrence of arrhythmia after a 90 day blanking period and other&#xD;
      relevant outcome measures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Safety Endpoint;Proportion of Intent to Treat Subjects with one or more of the specified device or procedure related SAEs</measure>
    <time_frame>7 days</time_frame>
    <description>Proportion of Intent to Treat subjects with one or more of the specified device or procedure related SAEsEndpoint(CSE) defined as the incidence of the following early-onset serious adverse events (SAEs) which are device- or procedure-related, as adjudicated by the Clinical Events and Data Monitoring Committee (CEDMC). Atrioesophageal fistula and PV stenosis components will be assessed for occurrence at any time during follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite Safety Endpoint;Proportion of Intent to Treat Subjects with one or more of the specified device or procedure related SAEs</measure>
    <time_frame>12 Months</time_frame>
    <description>Proportion of Intent to Treat subjects with one or more of the specified device or procedure related SAEsEndpoint(CSE) defined as the incidence of the following late-onset serious adverse events (SAEs) which are device- or procedure-related, as adjudicated by the Clinical Events and Data Monitoring Committee (CEDMC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Procedural Success; Acute Vein Success; Acute Chronic Success</measure>
    <time_frame>12 Months</time_frame>
    <description>Demonstration of Acute Vein Success in all attempted PVs using the FARAPULSE Cardiac Ablation System Plus during the first ablation procedure (Index or Rescheduled Index Procedure)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>FARAPULSE™ Endocardial Cardiac Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ablation using FARAPULSE™ Cardiac Ablation System Plus</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ablation</intervention_name>
    <description>Ablation using the FARAPULSE™ Cardiac Ablation System Plus</description>
    <arm_group_label>FARAPULSE™ Endocardial Cardiac Ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria: Patients are required to meet all the following inclusion criteria&#xD;
        to participate in this study:&#xD;
&#xD;
          -  Age 18-75 Patients with documented drug-resistant symptomatic persistent AF&#xD;
&#xD;
               1. Patient is refractory or intolerant to at least one Class I/III antiarrhythmic&#xD;
                  agent.&#xD;
&#xD;
               2. ECG-documented first episode of persistent AF, lasting longer than 7 days but not&#xD;
                  longer than 365 days&#xD;
&#xD;
               3. Holter within 90 days prior to the Enrollment Date demonstrating 24 hours of&#xD;
                  continuous AF 3. Patient participation requirements:&#xD;
&#xD;
               1. Lives locally&#xD;
&#xD;
               2. Is willing and capable of providing Informed Consent to undergo study procedures&#xD;
&#xD;
               3. Is willing to participate in all examinations and follow-up visits and tests&#xD;
                  associated with this clinical study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will be excluded from participating in this study if they meet any one of the&#xD;
        following exclusion criteria:&#xD;
&#xD;
          1. AF that is:&#xD;
&#xD;
               1. Paroxysmal (longest AF episode &lt; 7days)&#xD;
&#xD;
               2. Longstanding (has persisted &gt; 12 months or that does not respond to cardioversion&#xD;
                  if &lt; 12 months)&#xD;
&#xD;
               3. Secondary to electrolyte imbalance, thyroid disease, alcohol abuse or other&#xD;
                  reversible / non-cardiac causes&#xD;
&#xD;
          2. Left atrial anteroposterior diameter ≥ 5.5 cm as documented by transthoracic&#xD;
             echocardiography (TTE) or computed tomography (CT)&#xD;
&#xD;
          3. Any of the following cardiac procedures, implants or conditions:&#xD;
&#xD;
               1. Clinically significant arrhythmias other than AF, AFL or AT&#xD;
&#xD;
               2. Hemodynamically significant valvular disease&#xD;
&#xD;
               3. Prosthetic heart valve&#xD;
&#xD;
               4. NYHA Class III or IV CHF&#xD;
&#xD;
               5. Previous endocardial or epicardial ablation or surgery for AF&#xD;
&#xD;
               6. Atrial or ventricular septal defect closure&#xD;
&#xD;
               7. Atrial myxoma&#xD;
&#xD;
               8. Left atrial appendage device or occlusion&#xD;
&#xD;
               9. Pacemaker, implantable cardioverter defibrillator or cardiac resynchronization&#xD;
                  therapy devices&#xD;
&#xD;
              10. Significant or symptomatic hypotension&#xD;
&#xD;
              11. Bradycardia or chronotropic incompetence&#xD;
&#xD;
              12. History of pericarditis&#xD;
&#xD;
              13. History of rheumatic fever&#xD;
&#xD;
              14. History of congenital heart disease with any residual anatomic or conduction&#xD;
                  abnormality&#xD;
&#xD;
          4. Any of the following within 3 months prior toenrollment:&#xD;
&#xD;
               1. Myocardial infarction&#xD;
&#xD;
               2. Unstable angina&#xD;
&#xD;
               3. Percutaneous coronary intervention&#xD;
&#xD;
               4. Heart surgery (e.g. coronary artery bypass grafting, ventriculotomy, atriotomy)&#xD;
&#xD;
               5. Heart failure hospitalization&#xD;
&#xD;
               6. Stroke or TIA&#xD;
&#xD;
               7. Clinically significant bleeding&#xD;
&#xD;
               8. Pericarditis or pericardial effusion&#xD;
&#xD;
               9. Left atrial thrombus&#xD;
&#xD;
          5. History of blood clotting or bleeding abnormalities.&#xD;
&#xD;
          6. Contraindication to, or unwillingness to use, systemic anticoagulation&#xD;
&#xD;
          7. Contraindications to CT or MRI&#xD;
&#xD;
          8. Sensitivity to contrast media not controlled by premedication&#xD;
&#xD;
          9. Women of childbearing potential who are pregnant, lactating or not using birth control&#xD;
&#xD;
         10. Medical conditions that would prevent participation in the study, interfere with&#xD;
             assessment or therapy, significantly raise the risk of study participation, or&#xD;
             confound data or its interpretation, including but not limited to&#xD;
&#xD;
               1. Body mass index (BMI) &gt; 40&#xD;
&#xD;
               2. Solid organ or hematologic transplant, or currently being evaluated for an organ&#xD;
                  transplant&#xD;
&#xD;
               3. Severe lung disease, pulmonary hypertension, or any lung disease involving&#xD;
                  abnormal blood gases or significant dyspnea&#xD;
&#xD;
               4. Renal insufficiency with an estimated creatinine clearance &lt;30 mL/min/1.73 m2, or&#xD;
                  any history of renal dialysis or renal transplant&#xD;
&#xD;
               5. Active malignancy or history of treated cancer within 24 months of enrollment&#xD;
&#xD;
               6. Clinically significant gastrointestinal problems involving the esophagus, stomach&#xD;
                  and/or untreated acid reflux&#xD;
&#xD;
               7. Clinically significant infection&#xD;
&#xD;
               8. Predicted life expectancy less than one year&#xD;
&#xD;
         11. Clinically significant psychological condition that in the investigator's opinion&#xD;
             would prohibit the subject's ability to meet the protocol requirements&#xD;
&#xD;
         12. Current or anticipated enrollment in any other clinical study&#xD;
&#xD;
         13. Employment by FARAPULSE or the same hospital department or office of any investigator,&#xD;
             or a family member of any of the preceding groups.&#xD;
&#xD;
         14. Use of amiodarone after day of index ablation procedure. Patients will cease use of&#xD;
             amiodarone on or before the date of the index ablation procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christopher Schneider</last_name>
    <phone>650-422-3633</phone>
    <email>kschneider@farapulse.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anitha Achyutha</last_name>
    <phone>858-349-9550</phone>
    <email>aachyutha@farapulse.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nemocnice Na Homolce</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Neuzil</last_name>
      <phone>+420 257 272 211</phone>
      <email>Petr.Neuzil@homolka.cz</email>
    </contact>
    <contact_backup>
      <last_name>Petr Moucka</last_name>
      <phone>+420 257 272 392</phone>
      <email>Petr.Moucka@homolka.cz</email>
    </contact_backup>
    <investigator>
      <last_name>Petr Neuzil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 15, 2021</study_first_submitted>
  <study_first_submitted_qc>December 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>December 9, 2021</last_update_submitted>
  <last_update_submitted_qc>December 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

